Accumulation of pathologic tau protein plays a pivotal role in the neurodegeneration of Alzheimer’s disease (AD) and many other tauopathies. Thus, amelioration of pathological tau aggregates in the brain is an important direction for the development of drugs. However, since tau per se plays multifaceted physiological roles in maintaining cell structure and functions, the traditional strategies targeting the general form of tau proteins might be somewhat arbitrary.
This article was originally published on MedicalXpress.com
